Celltrion has announced that its CT-P42 proposed biosimilar to Eylea (aflibercept) has entered Phase III trials. A study on the efficacy, safety, pharmacokinetics and immunogenicity of its version in diabetic macular edema patients across 13 countries due to complete by the second half of 2022.
Celltrion Prepares Aflibercept For Phase III
Follows In Footsteps Of Denosumab, Omalizumab And Ustekinumab Biosimilars
Celltrion has announced that its latest biosimilar development project is progressing to Phase III trials, with its aflibercept rival to Eylea following recent advances for the Korean firm’s denosumab, omalizumab and ustekinumab candidates.
More from Biosimilars
More from Products
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.